Modinat Aina Abayomi

Modinat Aina Abayomi

Auto-generated profile, based on publicly available information

Modinat Aina Abayomi

Department of Biology, Boston College, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Advances in Biomarker Sciences and Technology
Verified
Journal Article
Open access
KRKayode Raheem
Kayode Raheem
FIFawehinmi Praise Ibukunoluwa
Fawehinmi Praise Ibukunoluwa
SOSolomon Ayodele Olorundare
Solomon Ayodele Olorundare
JNJairus Nandwa
Jairus Nandwa
MAModinat Aina Abayomi
Modinat Aina Abayomi
FDFalana Taiwo Daniel
Falana Taiwo Daniel

4 October 2025 in Epidemiology and Health Data Insights
Verified
Journal Article
Open access
PDF file
AAAbdulgafar Onikoko Ahmad
Abdulgafar Onikoko Ahmad
MAModinat Aina Abayomi
Modinat Aina Abayomi
OTObinna Hilary Tony-Okpalaobi
Obinna Hilary Tony-Okpalaobi
FOFaozyat Odunayo Odetola
Faozyat Odunayo Odetola
ONOgechi Njoku
Ogechi Njoku
DADorothy Abimbola Antai
Dorothy Abimbola Antai
Antimicrobial resistance (AMR) is a growing global threat, and sub-Saharan Africa (SSA) bears a disproportionate share of this burden. This narrative review examines how deficiencies in water, sanitation, and hygiene (WASH) contribute to AMR in SSA. It draws on peer-reviewed literature, institutional reports, and regional policy documents published between 2015 and 2025. Sources were identified through databases such as PubMed, Google Scholar, and WHO/UN databases using combinations of keywords including ‘AMR’, ‘WASH’, ‘Sub-Saharan Africa’, and ‘One Health’. We survey recent literature on the regional AMR problem, the role of inadequate WASH in propagating resistant infections among humans, animals, and the environment, and the relevance of a One Health approach. Key themes include the high AMR mortality in Africa, the persistence of antibiotic residues and pathogens in poorly managed water and sanitation systems, and how poverty-related WASH gaps drive frequent infections that require antibiotics. Evidence suggests that unsafe water and sanitation facilitate the environmental circulation of resistant bacteria and genes. The One Health framework is highlighted as essential for addressing these links, since AMR crosses human, animal, and ecological domains. We conclude that improving WASH infrastructure and practices, alongside integrated AMR strategies, is critical to curb resistance in the region. Focusing on WASH under a One Health perspective can reveal overlooked pathways of AMR spread and inform targeted interventions in SSA.

19 September 2025 in Australian Journal of Biomedical Research
Verified
Journal Article
Open access
PDF file
SASalvation Ifechukwude Atalor
Salvation Ifechukwude Atalor
ASAliaa Mohammed Mahmoud Soliman
Aliaa Mohammed Mahmoud Soliman
OAOluwatobiloba Kehinde Adedokun
Oluwatobiloba Kehinde Adedokun
AAAbayomi Modinat Aina
Abayomi Modinat Aina
CUCecilia Chika Unegbu
Cecilia Chika Unegbu
AOALIYU OLANREWAJU OLANIYI
ALIYU OLANREWAJU OLANIYI
Background: Small-molecule drugs have transformed oncology, but conventional inhibitors are limited by resistance, restricted target scope, and declining durability. Methods: We reviewed emerging small-molecule modalities—molecular glues, covalent inhibitors, and radiotheranostics—focusing on their mechanisms, clinical applications, and translational challenges. Key clinical trials and representative examples were identified from recent oncology literature. Results: Molecular glues enable targeted degradation of previously undruggable proteins, with clinical success in multiple myeloma (IMiDs). Covalent inhibitors achieve durable suppression of oncogenic drivers such as KRAS^G12C and BTK, as shown in CodeBreaK100 (sotorasib; N=126; ORR 37%). Radiotheranostics combine imaging and therapy, exemplified by VISION (PSMA-617; N=831; OS HR 0.62) and NETTER-1 (Lutathera; N=229; PFS HR 0.21). Collectively, these modalities expand the druggable proteome, improve durability, and advance precision oncology. Conclusion: Emerging small-molecule approaches mark a paradigm shift from inhibition alone to targeted degradation, durable covalent engagement, and diagnostic–therapeutic hybrids. Future priorities include improving selectivity, biomarker integration, scalable manufacturing, and equitable global access.

3 February 2026 in Journal of Contemporary Studies in Epidemiology and Public Health
Verified
Journal Article
Open access
VNVivian Ukamaka Nwokedi
Vivian Ukamaka Nwokedi
MAModinat Aina Abayomi
Modinat Aina Abayomi
AAAhmad Onikoko Abdulgafar
Ahmad Onikoko Abdulgafar
NENdubisi Ubaka Edebeatu
Ndubisi Ubaka Edebeatu
ONOgechi Njoku
Ogechi Njoku
Vulnerable populations all around the world, especially those in low-resource settings, continue to suffer the consequences of neglected tropical diseases (NTDs). Methods of diagnosis that are considered traditional are frequently insufficient when it comes to the successful identification and management of NTDs related issues. This study examines how novel diagnostic technologies improve diagnosis accuracy, accessibility, and cost-effectiveness for NTD management. In carrying out this review, a scoping review was adopted using PubMed and grey literature sources. The search yielded 336 articles, of which 23 were selected through title and abstract screening. After reviewing the complete text, 9 studies met the eligibility criteria for inclusion. New diagnostic techniques like rK39 and rK28 NTDs, molecular diagnostics, and point-of-care testing showed better sensitivity, specificity, and accessibility than older methods. Studies also showed that they might be used in the field to improve disease surveillance and treatment uptake, especially for visceral leishmaniasis, schistosomiasis, and lymphatic filariasis. The use of innovative diagnostic technologies is very helpful for controlling NTDs because they make it easier to get accurate diagnoses in places where resources are limited. Subsequent study must concentrate on the expansion of these technologies, the resolution of infrastructural constraints, and the investigation of their contribution to global efforts in the eradication of NTDs.

6 November 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
KRKayode Raheem
Kayode Raheem
MAModinat Abayomi
Modinat Abayomi
OAOluwatosin Maryam Adeyemo
Oluwatosin Maryam Adeyemo
MAMary Adewunmi
Mary Adewunmi
IAIjaz Ali
Ijaz Ali
OAOluwatosin Adeyemo
Oluwatosin Adeyemo
Triple-negative breast cancer (TNBC) is a deadly form of breast cancer that lacks estrogen, progesterone, and HER2 receptors. The development of drugs for TNBC has been challenging due to the lack of specific therapeutic targets. However, recent studies have shown that targeting the ATP active of the PDK-1 and PLK-1 proteins could be potential drug targets for TNBC treatment. New medications for TNBC have considerable adverse effects, highlighting the need for more targeted and effective therapies. In this study, we employed various computational approaches, including molecular docking, molecular dynamics (MD) simulations, pharmacokinetic studies, binding free energy calculations, principal component analysis (PCA), and alanine scanning analysis, to identify bioactive compounds from Daucus carota- extracted natural compounds that can bind to these ATP-binding sites and inhibit the activity of PDK1 and PLK1. Our study revealed that eight compounds showed reasonably good docking scores, binding free energies, and ADMET properties against the PDK1 and PLK1 enzymes. Astragalin and scolimoside showed substantial binding affinity and persistent interactions in the pocket region of the two proteins. Further MD simulation studies for 150 ns also suggested that the compounds were stably bound in the active site with very minor fluctuations. We believe that the identified hits for PDK1 and PLK1 from Daucus carota will be effective against TNBC in performing the biological assays.

31 August 2025 in arXiv
Verified
Preprint
Open access
PDF file
RAReem Abdel‐Salam
Reem Abdel‐Salam
MAMary Adewunmi
Mary Adewunmi
MAModinat A. Abayomi
Modinat A. Abayomi
Large language models (LLMs) are increasingly evident for accurate question answering across various domains. However, rigorous evaluation of their performance on complex question-answering (QA) capabilities is essential before deployment in real-world biomedical and healthcare applications. This paper presents our approach to the MedHopQA track of the BioCreative IX shared task, which focuses on multi-hop biomedical question answering involving diseases, genes, and chemicals. We adopt a supervised fine-tuning strategy leveraging LLaMA 3 8B, enhanced with a curated biomedical question-answer dataset compiled from external sources including BioASQ, MedQuAD, and TREC. Three experimental setups are explored: fine-tuning on combined short and long answers, short answers only, and long answers only. While our models demonstrate strong domain understanding, achieving concept-level accuracy scores of up to 0.8, their Exact Match (EM) scores remain significantly lower, particularly in the test phase. We introduce a two-stage inference pipeline for precise short-answer extraction to mitigate verbosity and improve alignment with evaluation metrics. Despite partial improvements, challenges persist in generating strictly formatted outputs. Our findings highlight the gap between semantic understanding and exact answer evaluation in biomedical LLM applications, motivating further research in output control and post-processing strategies.